Prilenia’s Phase 3 ALS Study Reaches Approximately 60% Enrollment

• Prilenia and Ferrer’s Phase 3 PREVAiLS study of pridopidine in early-stage ALS is approximately 60% enrolled.
• Recruitment of approximately 500 participants is expected to finish in Q1 2027, with top-line results due in Q1 2028.
• Post hoc HEALEY Phase 2 trial and extension analysis included 36 ALS participants within 18 months of symptom onset.
• Investigational pridopidine showed positive functional, respiratory and median survival results through Week 48 versus propensity-score-matched external PRO-ACT controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.